Background Hyperglycaemia is associated with increased risk of cardiovascular complications in people with type 2 diabetes. We investigated whether reduction of blood glucose concentration decreases the rate of microvascular complications in people with type 2 diabetes.
Introduction
Epidemiological studies of type 2 diabetes have shown that high blood glucose concentrations, as established by measurement of haemoglobin A 1c (HbA 1c ) concentration, are associated with an increased risk of diabetic retinopathy, nephropathy, and neuropathy. [1] [2] [3] [4] [5] [6] Results of several clinical trials aimed at reducing HbA 1c concentrations have shown that intensive glycaemic control in patients with type 2 diabetes is associated with a reduction in microvascular complications (mostly in albuminuria). [7] [8] [9] [10] The glycaemia arm of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial 11 was an investigation of the eff ects on cardiovascular events of intensive versus standard glycaemia control therapy for hyperglycaemia in a large population with type 2 diabetes.
12 Besides the primary composite cardiovascular endpoint, the ACCORD trial had predefi ned secondary endpoints to assess the eff ect of intensive glycaemia therapy on incidence and progression of retinopathy, nephropathy, and neuropathy.
ACCORD targeted near-normal glycaemia in people with longstanding type 2 diabetes (mean 10 years) and cardiovascular disease or high cardiovascular risk. The intensive therapy aimed to reduce HbA 1c values to less than 6·0%, whereas the standard therapy sought to keep values between 7·0% and 7·9%, with a mean of 7·5%. 11 As reported, 11 HbA 1c concentrations achieved with the intensive therapy were much lower than those achieved in UKPDS 7 and VADT, 13 and were similar to those in the ADVANCE trial, 9 which reported results from people with a similar duration of diabetes as in ACCORD. HbA 1c concentrations in the standard treatment group in ACCORD were lower than those achieved in UKPDS and VADT, and were similar to those reported in ADVANCE. For participants with surveillance for one or more microvascular outcomes, the intensive glycaemia control was stopped in February, 2008, after a median of 3·7 years (IQR 2·7-4·3) of follow-up because of an increase in allcause mortality.
14 However, these participants continued in the trial with the standard therapy for the planned remainder of the median 5·0 years (4·2-5·7) of follow-up to June, 2009 .
Here, we report results of predefi ned secondary microvascular outcomes at transition of patients from intensive to standard therapy, and at the end of the full duration of the trial. The eff ect of glycaemia control strategies on diabetic retinopathy including fundus photography in a subset of patients is the protocol-defi ned main microvascular endpoint in ACCORD, and is published separately as the ACCORD-EYE study. 15 
Methods

Study design and participants
We recruited volunteers who had type 2 diabetes mellitus, HbA 1c concentrations of 7·5% or more, and were aged 40-79 years with history of cardiovascular disease or 55-79 years with anatomical evidence of signifi cant atherosclerosis, albuminuria, left ventricular hypertrophy, or at least two risk factors for cardiovascular disease (dyslipidaemia, hypertension, being a smoker, or obesity). Exclusion criteria included frequent or recent serious hypoglycaemic events, unwillingness to monitor glucose at home or inject insulin, body-mass index of more than 45 kg/m², serum creatinine more than 132·6 μmol/L, or other serious illness. Participants were recruited at 77 clinical centres (aggregated within seven networks) in the USA and Canada. Ethics committees at every institution approved the protocol and the written informed consent forms.
ACCORD was a double two-by-two factorial, parallel treatment trial (fi gure 1) in which patients were randomly assigned to receive one of two glycaemia control strategies: intensive treatment targeting a HbA 1c concentration of less than 6·0% or standard treatment targeting HbA 1c of 7·0-7·9%. Patients were also assigned to one of two blood pressure interventions (intensive blood pressure target <120 mm Hg, or standard <140 mm Hg), or a lipid intervention (fenofi brate or placebo while maintaining good control of LDLcholesterol with simvastatin). Recruitment was done in two stages. The vanguard phase recruitment was between January, 2001, and May, 2001 , and treatment and followup was done until February, 2003; recruitment of participants in the main trial phase was between March, 2003, and October, 2005 . Treatment and follow-up of all participants was done until June, 2009. Participants were given instructional materials and behavioural counselling as part of their glycaemic intervention, and were provided with glucose-lowering drugs and self-monitoring supplies. Treatment regimens were individualised by study investigators (with feedback from patients) on the basis of randomised assignment and response to therapy. Adverse eff ects were monitored both locally and centrally to ensure participant safety.
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Prespecifi ed microvascular outcomes in ACCORD were measures of kidney function, diabetic eye complications, and peripheral neuropathy. Two composite outcomes were prespecifi ed (table 1). The fi rst combined advanced kidney and eye disease and was intended to approximate the primary microvascular outcome of the UKPDS study, 16 and the second added peripheral neuropathy to that outcome. Table 1 summarises the predefi ned ACCORD microvascular outcomes and their frequency of assessment. The primary microvascular outcome based on all ACCORD participants was predefi ned as the fi rst composite endpoint (development of renal failure, or retinal photocoagulation or vitrectomy to treat diabetic retinopathy), which is characterised as advanced microvascular disease. We assessed individual components of the microvascular outcomes with the standard procedures described in webappendix pp 1-2.
Randomisation and masking
Randomisation in the vanguard phase was stratifi ed by clinical centre network and baseline cardiovascular disease status (either primary or secondary prevention) with permuted blocks of four, eight, or 12 patients. In the main trial, randomisation was stratifi ed only by clinical site to improve balance within the 77 clinical sites with the same block sizes. Because of the improved refi nement in stratifi cation during the main trial, baseline cardiovascular disease status was dropped as a stratifi cation factor.
Unique randomisation sequences were computer generated for every clinical site centrally at the coordinating centre. Randomisation was done by clinical staff via secure access to the ACCORD trial website. Electronic verifi cation of inclusion and exclusion criteria was done before patients were assigned to a treatment 
Statistical analysis
ACCORD's sample size of 10 000 was designed to have 89% power to detect a 15% treatment eff ect of intensive glycaemic control compared with standard glycaemic control on the primary composite outcome of cardiovascular disease-death from cardiovascular causes, non-fatal myocardial infarction, or non-fatal stroke. Descriptive statistics of a subset of continuous factors related to treatment in every trial were calculated by glycaemia treatment group at the date of transition from intensive to standard therapy for the glycaemia trial and again at study end. Diff erences in these factors were assessed by use of the Wilcoxon signed-rank test. Table 1 describes microvascular events for every predefi ned outcome. For each patient and outcome, observation was censored at the last surveillance time if no event was recorded. If an event was reported, an event time was assigned with the midpoint between the time of event discovery and the most recent previous surveillance time. 18 Interim analyses of intervention eff ectiveness were done every 6 months for meetings of the data safety and monitoring board. Overall type 1 error was controlled via the group sequential procedure of Lan and DeMets. 19 Two sets of analyses were done. The fi rst assessed outcomes before transition (Feb 5, 2008) , and the second assessed all outcomes until the last study visit (March-June, 2009 ).
The eff ect of the diff erent glycaemia control therapies on time to occurrence of the fi rst microvascular event of every type was analysed with proportional hazards regression models to estimate hazard ratios and assess statistical signifi cance. Graphical depiction of time to event was done with Kaplan-Meier plots. The main statistical test for every outcome was taken from a model that accounted for glycaemia treatment group assignment, second trial treatment group assignment (intensive or standard blood pressure management in the blood pressure trial, or fenofi brate or placebo assignment in the lipid trial), and an indication of history of clinical cardiovascular disease at baseline as prespecifi ed in the study protocol. The proportional hazards assumption was assessed by examination of log(-log[survival]) plots. Analysis of the plots showed that the assumption of proportional hazards was tenable.
Analyses included participants with microvascular assessment, who were analysed on the basis of treatment assignment irrespective of treatments received or compliance to therapies. No p-value correction was applied to account for multiple hypothesis tests. 20 Outcomes presented in this Article were prespecifi ed and future analyses will be done to 
Role of the funding source
Staff from the National Heart, Lung, and Blood Institute (the sponsor of ACCORD) served on the Executive and Steering Committees in which decisions on study design, intervention approaches, data collection, analysis, interpretation, and review of reports were made. The corresponding author had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication.
Results
10 251 participants were assigned to therapy. 1174 participants were randomly assigned in the vanguard phase with an additional 9077 randomised during the main trial. Figure 2 shows the process of screening and randomisation. Participants had a median age of 62 years (IQR 57-67), and type 2 diabetes for around 10 years. Tables 2 and 3 show continuous and categorical baseline participant characteristics by glycaemia intervention group assignment. When the ACCORD intensive glycaemia control was discontinued (at transition to standard therapy), the two glycaemia groups diff ered with respect to median HbA 1c (p<0·0001; table 4). At study end, median HbA 1c concentration was still signifi cantly lower in participants who had previously been intensively managed than in those in the standard group (p<0·0001). Systolic and diastolic blood pressures were signifi cantly reduced from baseline in both groups at the time of transition, and remained so at study end (table 4) . HDL concentrations were slightly higher in both men and women in the intensive group at transition compared with stan dard treatment. Triglyceride concentrations were 0·16 mmol/L lower in the intensive target group than in the standard glycaemia group at transition; and a small diff erence remained at study end. As previously reported, 14 the intensive therapy group had a signifi cantly higher bodymass index at transition than did the standard group, and the diff erence remained at study end. Serum creatinine concentrations were not diff erent between the two groups at transition or at study end. The median ratio of albumin to creatinine was signifi cantly lower in the intensive group than it was in the standard group at both transition and study end (table 4) .
The primary composite outcome of advanced nephropathy and diabetic eye complications (table 1) did not diff er between groups at transition (fi gures 3 and 4) or at study end (fi gure 5). The second composite endpoint, which added a peripheral neuropathy outcome to the primary composite outcome, also did not diff er at transition (fi gure 4) or at study end (fi gure 5).
Microvascular renal outcomes based on urinary measurements were signifi cantly reduced in the intensive glycaemia group. Intensive glycaemia therapy led to a 21% reduction in development of microalbuminuria at transition (fi gure 4); this eff ect was attenuated (15%) but remained signifi cant at study end (fi gure 5). Incidence of macroalbuminuria was reduced in the intensive group compared with the standard group at transition and at study end (fi gures 4 and 5). The number of patients with overt renal failure was alike in both groups at study end (fi gure 5). There was a signifi cant diff erence between the groups at transition in the microvascular renal outcome based on serum creatinine or estimated glomerular fi ltration rate (eGFR) that favoured the standard glycaemia group (fi gure 4); although the diff erence was not signifi cant at study end. The diff erence between treatment groups in this renal outcome was attributable to a decline in eGFR in the intensive group in the fi rst 24 months, possibly because of a decrease in glomerular hyperfi ltra tion associated with improved glycaemic control (fi gure 6); serum creatinine and eGFR concentrations remained within the normal range. A composite of prespecifi ed renal outcomes-not including incident micro albuminuriadid not diff er between groups at transition or study end (Neph-5 outcome; fi gures 4 and 5). At study end, there was no diff erence in microvascular renal outcomes between groups, apart from microalbuminuria and macro albuminuria (fi gure 5). For diabetes-related eye events, three-line worsening of visual acuity was more common in the standard group than in the intensive group at transition and at study end (fi gures 4 and 5). Cataract extraction was also signifi cantly reduced (by 21%) in the intensive group compared with standard group at study end (fi gure 5). Other diabetes-related eye outcomes did not diff er signifi cantly between the two groups.
Peripheral neuropathy, as established by a Michigan neuropathy screening instrument score of 2·0 or more, was less common in the intensive group than in the standard therapy group at study end (fi gure 5). Loss of ankle jerk refl ex and light touch (10 g monofi lament) perception were both rarer in the intensive than in the standard therapy at study end (fi gure 5); light touch was also reduced at transition (fi gure 4). Loss of vibratory sensation did not diff er signifi cantly between the two groups. The webappendix contains Kaplan-Meier plots of all secondary microvascular outcomes.
Discussion
We recorded no signifi cant eff ect of intensive glycaemia therapy on the two prespecifi ed composite microvascular outcomes-1) advanced renal or eye complications, or 2) these two outcomes or peripheral neuropathy.
Microvascular complications including nephropathy, retinopathy, and neuropathy are an important source of morbidity in patients with type 2 diabetes. Analysis of available epidemiological evidence suggests that hyperglycaemia is an important contributor to develop ment and progression of microvascular complications in type 2 diabetes. 6 Although some clinical trials 4, 7, 8 reported a decrease in occurrence of micro vascular endpoints with lowering of HbA 1c , fi ndings from recent trials 9,13 showed less benefi t in elderly patients or those with long-term diabetes than in younger patients or those with shortduration disease.
Results of the UKPDS 7 showed a decrease with intensive treatment in the composite retinal-renal outcome used by ACCORD, with a smaller reduction in HbA 1c than was attained in ACCORD. However, the UKPDS cohort was younger than in ACCORD, was studied from the time of diagnosis of diabetes, and was treated intensively for 11 years, albeit with a higher HbA 1c concentration than was achieved in ACCORD. 7 Analysis of secondary renal endpoints shows that the risk of development of macroalbuminuria was 29% lower with intensive therapy both at transition and at study end than with standard therapy. Macroalbuminuria is a known risk factor for renal insuffi ciency 21 and cardiovascular disease. 22 We noted reductions in albuminuria with intensive glycaemia therapy similar to those in the ADVANCE 9 and VADT 13 trials. Collectively, these fi ndings emphasise the benefi ts of glycaemic control for reduction of abluminuria in an important group of patients with type 2 diabetes (ie, elderly patients, and those with long-term disease or with established cardiovascular disease or high cardiovascular risk). The increase noted in the composite outcome of doubling of serum creatinine or a 20 mL/min or more decrease in eGFR with intensive therapy was largely attributable to a slight and transient diff erential increase in serum creatinine in the intensive group during the fi rst 2 years of the trial. Mean serum creatinine concentrations at baseline, transition, and end of study were similar in the two treatment groups (tables 2-4).
By contrast with UKPDS, 7 we did not record a clear benefi t of intensive therapy for diabetic retinopathy on the basis of major clinical endpoints (such as necessity of photo coagulation); our result is consistent with VADT 9 and ADVANCE. 13 The signifi cant reductions in the development of peripheral neuropathy, if further sustained, suggest that intensive glycaemia therapy could decrease the risk of ulcers and number of future leg amputations. Serum creatinine (μmol/L) 4395
Urine albumin:creatinine ratio (mg/mmol)
Data are mmol/L unless otherwise stated. *Data restricted to measurements within 1 year of transition date apart from urine albumin:creatinine ratio, which was within 2 years of transition. HbA 1c =haemoglobin A 1c . Table 4 : Patient characteristics at transition to standard glycaemic therapy and at end of study, by glycaemia treatment group assignment 
Figure 4: Comparison of intensive and standard glycaemic therapy for all microvascular outcomes, until transition
Intensive therapy was stopped before study end because of increased mortality, and patients were transitioned to standard therapy. Hazard ratios adjusted for baseline clinical cardiovascular disease history and second trial treatment group assignment. NNT=number needed to treat. ESRD=endstage renal disease (defi ned as requirement of dialysis or serum creatinine concentration of more than 291·72 μmol/L). SCr=serum creatinine. eGFR=estimated glomerular fi ltration rate. MNSI=Michigan neuropathy screening instrument score. *Defi ned as Snellen fraction <20/200. 
The benefi cial eff ects of intensive therapy on surrogate secondary microvascular outcomes compared with standard therapy should be balanced against observed risks. The 22% relative and 0·27% per year absolute increase in all-cause mortality recorded with intensive glycaemia therapy in ACCORD prompted the discontinuation of intensive glycaemia control and transition of patients to standard glycaemia therapy. 14 Additionally, intensive therapy led to increased bodymass index and a three-fold increase in frequency of severe hypoglycaemia. 14 Furthermore, no overall cardiovascular disease benefi t had accrued, although non-fatal myocardial infarction was reduced by 24% (p=0·004).
14 In subgroup analysis, there was a reduction in the primary composite cardiovascular disease outcome (but not in total mortality) in patients who entered the study with no previous history of cardiovascular disease events or with an HbA 1c of 8·0% or less.
14 Overall, targeting of HbA 1c of 6·0% or less with the methods used for the ACCORD cohort is not recommended on the basis of the microvascular benefi ts associated with intensive glycaemia therapy. Any benefi ts should be weighed against the recorded increase in total and cardiovascular disease-related mortality, increased weight gain, and increased risk of severe hypoglycaemia in intensively-treated patients.
In this multicentre trial, we tried to adhere to the intention-to-treat principle for analysis of data from baseline to transition, and from baseline to study end, analysing all participants who were assessed for microvascular outcomes. The signifi cant diff erence noted in the mean HbA 1c concentration of the two originally randomised treatment groups persisted from transition to the end of the study. The diff erences in HbA 1c during follow-up exceeded those reported by the UKPDS 7 and ADVANCE, 9 but was less than that achieved in VADT. 13 Loss to follow-up were very low. One limitation was that investigators were not masked to treatment strategies or outcomes. Another was that follow-up might have been too short to show eff ects of treatment on some endpoints. In UKPDS, cardiovascular and microvascular benefi ts persisted or became increasingly evident after 10 years. Although not generally accepted, 24 a post-hoc power analysis for the primary composite outcome in our study showed 66% power to detect a 15% risk reduction in the intensive glycaemia group at transition, and 82% at the end of the investigation. A similar analysis for the second composite outcome showed powers of 87% to detect a 10% risk reduction at transition and 92% at end of study. Another limitation was that the ratio of albumin to creatinine instead of a timed albumin excretion rate was measured in ACCORD. However, good correlation between the two measures of albumin excretion rate has been noted, 25, 26 although variable intraindividual correlation 27 and regression of the albumin to creatinine ratio to normal has also been reported. [28] [29] [30] Furthermore, the eGFR is not validated as an accurate measure of changes in glomerular fi ltration rate in patients without sig nifi cant renal disease. Although ACCORD investi gators were trained centrally to do tests for neuropathy, they were not certifi ed for the procedure.
Analytical limitations included the use of midpoint interval imputation for calculation of survival times in outcomes for which time of event was unknown. Surveillance intervals for all outcomes were less than 2 years, and some outcomes were assessed every 4 months or 12 months. Law and Brookmeyer, 18 in their examination of the eff ect of midpoint imputation on doubly censored survival data, showed that traditional survival techniques provide an adequate approximation of survival estimates in large samples with intervals of 2 years or less. Finally, because 15 outcomes were assessed, if we had done independent tests, there would be a 54% chance (ie, 1−[1−0·05]¹⁵) of at least one type I statistical error for both transition and end of study analyses. 31 The observed benefi ts associated with intensive glycaemia management should be weighed against higher total and cardiovascular-related mortality, weight gain, and severe hypoglycaemia in patients at high risk of cardiovascular disease. Hence, caution should be exercised in pursuit of a strategy of intensive glycaemic control for prevention of microvascular complications in patients with established type 2 diabetes and characteristics similar to those in the ACCORD trial. An HbA 1c target of 6·0% or less with present strategies seems imprudent. Long-term assessment of benefi ts versus risks should be done through follow-up of the ACCORD participants. Contributors FI-B implemented the protocol and was lead author. TC coordinated the methods section and did the statistical analysis. MAB contributed to the methods section. JB, RC, LK, US, and AT contributed to the results section. JC, RMC, BH, PO'C, RP-B, and DW contributed to the results and discussion sections. WCC and RHG contributed to the design and implementation of the protocol and to the discussion section. SG contributed to the design and implementation of the protocol, and coordinated the discussion section. BPH and AK contribution to the discussion section. DK coordinated the introduction section. DS contributed to the methods, results, and discussion sections. HT contributed to the methods and discussion sections. IH coordinated the results section. All authors approved the fi nal report.
